% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hamacher:274583,
      author       = {R. Hamacher$^*$ and H. Lanzafame$^*$ and I. A.
                      Mavroeidi$^*$ and K. M. Pabst$^*$ and L. Kessler$^*$ and P.
                      F. Cheung$^*$ and S. Bauer$^*$ and K. Herrmann$^*$ and H.-U.
                      Schildhaus$^*$ and J. Siveke$^*$ and W. P. Fendler$^*$},
      title        = {{F}ibroblast {A}ctivation {P}rotein {I}nhibitor
                      {T}heranostics: {T}he {C}ase for {U}se in {S}arcoma.},
      journal      = {PET clinics},
      volume       = {18},
      number       = {3},
      issn         = {1556-8598},
      address      = {Orlando, Fla. [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-00660},
      pages        = {361-367},
      year         = {2023},
      note         = {2023 Jul;18(3):361-367},
      abstract     = {The theranostic use of fibroblast activation protein
                      inhibitors (FAPIs) is a novel approach in oncology. Sarcomas
                      are a heterogenous group of rare malignant tumors. Prognosis
                      remains poor in advanced/metastatic disease due to limited
                      therapeutic options. Sarcoma frequently demonstrate high
                      expression of fibroblast activation protein alpha on the
                      tumor cells themselves, in contrast to other solid tumors,
                      where it is mainly expressed on cancer-associated
                      fibroblasts. Consequently, high in vivo uptake of FAPI in
                      PET is observed in sarcoma. Moreover, retrospective case
                      reports and series demonstrated feasibility of FAPI
                      radioligand therapy with signs of tumor response.},
      subtyp        = {Review Article},
      keywords     = {FAP-Alpha (Other) / FAPI (Other) / Oncology (Other) / PET
                      (Other) / Radioligand (Other) / Sarcoma (Other) / Therapy
                      (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36997366},
      doi          = {10.1016/j.cpet.2023.02.008},
      url          = {https://inrepo02.dkfz.de/record/274583},
}